Makhosandile Zulu Nelisiwe Ngcobo was part of a study of the BPaL regimen treatment after enduring a 'very, very difficult' treatment course. A scientist in 2018 in France studies tuberculosis, a multidrug-resistant form of which could require a shorter treatment plan than previously, according to a 2019 study in a US journal. Picture: AFP/File/Anne-Christine Poujoulat A clinical programme will enrol 400 people in South Africa for treatment with a three-drug, six-month, all-oral regimen of bedaquiline, pretomanid and linezolid, known as the BPaL regimen, that has been shown to demonstrate a favourable outcome in 90% of patients of highly drug-resistant forms of TB.